This review highlights m6A's role in NSCLC progression and its potential as a diagnostic biomarker, suggesting new therapeutic strategies to overcome challenges.
Key Points
M6A modification significantly impacts tumor proliferation, apoptosis, and metastasis in non-small cell lung cancer.
The regulatory networks of m6A influence metabolic reprogramming, including glycolysis and ferroptosis in lung cancer.
Challenges in translating m6A-targeted therapies into clinical practice include detection method standardization and regulatory complexity.
Future research should leverage multi-omics to enhance our understanding of m6A and its potential in precision oncology.